Key facts
- It has raised $165.0M across 2 recorded rounds; the latest was Later Stage VC ($90.0M) in Mar 2024.
- 6 institutional filers report fund marks on Enliven Therapeutics across 76 filings.
- Enliven Therapeutics has filed 1 Form D with the SEC, most recently Apr 2024 ($90.0M sold to 20 investors).
Free account
See the evidence behind this price
- ·Post-money valuations for all 2 rounds
- ·Watchlist + deal alerts for Enliven Therapeutics
Create free account
No card required
Funding rounds
2 roundsFeb 2023PIPE$165.0M▮
About Enliven Therapeutics
- Industry
- Drug Discovery
PA Mark — not yet priced
Enliven Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Pro members can request priority coverage with a 48-hour turnaround.
Recorded secondary trades
No prints on record
No secondary trades in Enliven Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Pro members can request priority coverage with a 48-hour turnaround.
Institutional fund marks
6 filers · latest Jun 20266 SEC-registered funds reported 76 fair-value marks on Enliven Therapeutics between Apr 2025 and Jun 2026. Filer-level marks and implied $/share are available to Pro members.